CClinicalTrials.gg
RecruitingNCT07319143Updated May 4, 2026

The Effect of Transcranial Direct Current Stimulation (tDCS) in Improving Emotion Health

An interventional study of Transcranial Direct Current Stimulation and Sham tDCS in Subthreshold Depression, Positive Emotions and Negative Emotions, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by The University of Hong Kong · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The goal of this clinical trial is to investigate how transcranial direct current stimulation (tDCS) affects emotion functions in young adults aged 18-35 from the local community, including both male and female participants. The main question[s] it aims to answer are:

  • Does tDCS improve emotional functions, such as mood regulation and motivation, in individuals with subthreshold depression (StD)?
  • Can tDCS enhance emotional regulation compared to a sham stimulation (placebo)?

Researchers will compare participants receiving tDCS on either the left dorsolateral prefrontal cortex (lDLPFC) or right ventrolateral prefrontal cortex (rVLPFC) with those receiving sham stimulation to see if tDCS has a stronger effect on emotional functions.

Participants will:

  • Complete online and in-person screening to assess depressive symptoms using the Chinese version of the Beck Depression Inventory II (C-BDI-II) and be selected based on their depressive symptoms (C-BDI-II score ≥ 13).
  • Be randomly assigned to one of three groups: lDLPFC tDCS, rVLPFC tDCS, or Sham control group (1:1:1 ratio).
  • Receive 10 sessions of tDCS or Sham tDCS over 2 weeks, with each session lasting 20 minutes.
  • Complete assessments at baseline, post-intervention, 1-month follow-up, and 3-month follow-up, with each assessment lasting 2-2.5 hours. This includes questionnaires and perform emotional and cognitive tasks.
02

Conditions studied

  • Subthreshold Depression
  • Positive Emotions
  • Negative Emotions
  • Anhedonia

Browse trials for

Keywords

  • Transcranial Direct Current Stimulation
  • Subthreshold Depression
  • Emotion
  • Neuromodulation
03

In context

Anhedonia

119 studies on the registry are indexed under Anhedonia; 44 are open to participants now.

This study's planned enrollment of 90 is above the median of 70 across 99 interventional studies indexed under Anhedonia.

Browse Anhedonia studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,262 studies on the registry; 340 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 18-35 years
  • Fluency in Cantonese or Mandarin
  • Normal or corrected-to-normal vision and hearing
  • IQ > 75% Quantile in Raven's SPM
  • At least 9 years of formal education
  • Right-handedness

Exclusion criteria

Exclusion Criteria:

  • Past or current major physical illness or psychiatric disorders
  • Use of psychotropic medication in the past 6 months
  • Pregnancy (for women)
  • Any condition that prevents safe tDCS use (e.g., brain injury, implants)
  • Previous participation in neuromodulation in the past 3 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    IDLPFC tDCS

    This intervention is a 20 minutes per session, two-week tDCS neuromodulation of IDLPFC region (anode: F3, cathode: FP2) designed to reduce depressive symptoms via enhancing positive emotion functions, thereby reducing anhedonia.

    Device: Transcranial Direct Current Stimulation

  • Experimental
    rVLPFC tDCS

    This intervention is a 20 minutes per session, two-week tDCS neuromodulation of rVLPFC region (anode: F6, cathode: FP1) designed to reduce depressive symptoms via regulating negative emotion functions, thereby reducing depressed mood.

    Device: Transcranial Direct Current Stimulation

  • Sham comparator
    Sham tDCS

    This is a 20 minutes per session, two-week Sham comparator of IDLPFC/rVLPFC region, participants will receive tDCS for 30 seconds at either IDLPFC/rVLPFC at the beginning of each session to stimulate real neuromodulation.

    Device: Sham tDCS

Interventions

  • DeviceTranscranial Direct Current Stimulation

    TDCS is a non-invasive, safe, inexpensive, convenient and effective method to modulate brain and emotion functions. During tDCS, a mild electric current is passed between the anodal and cathodal electrodes on the scalp, which respectively excites and inhibits local and downstream neuronal activity, as well as modulating interregional connectivity strength. Compared to other neurostimulation methods such as Transcranial Magnetic Stimulation, tDCS side effects tend to be milder and transient, even if being administered for multiple sessions, making it suitable to be widely applied on clinical and subclinical populations.

    Also known as: tDCS

  • DeviceSham tDCS

    The sham tDCS delivers actual stimulation for 30 seconds only, while providing similar psychological perceptions to participants as the real intervention. Thus, the sham tDCS serves as an active control condition to the tDCS interventions.

06

What researchers measure

Primary outcomes

  1. Depressive symptoms

    The Beck Depression Inventory-II Chinese Version measures change in depressive symptoms. The total score range is 0-63, higher score indicates more severe depressive symptoms.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

Secondary outcomes

  1. Affective trait

    The Chinese Affect Scale measures changes in positive and negative affective traits. Both the positive affect and the negative affect subscales have a score range of 0-40, with higher scores indicating higher levels of positive affect trait and negative affect trait respectively.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  2. Anhedonia severity

    The dimensional anhedonia rating scale measures change in anhedonia severity on distinct physical/social domain. The scale comprises four subscales: Hobbies (4 items; score range 0-16), Food/Drink (4 items; score range 0-16), Social Activities (4 items; score range 0-16), and Sensory Experience (5 items; score range 0-20), with higher scores on each subscale indicating less anhedonia severity within the corresponding domain.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  3. Anhedonia symptoms

    The Chapman Physical/Social Anhedonia scales assess change in anhedonia symptoms in physical and social domains. The Chapman Physical Anhedonia Scale consists of 61 true-false items with a total score range of 0-61, and the Chapman Social Anhedonia Scale consists of 40 true-false items with a total score range of 0-40. For both scales, higher scores indicate higher levels of anhedonia.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  4. Behavioural motivation trait

    The Behavioural Activation and Inhibition Scale measures change in reward-driven approaching and punishment-driven avoidance tendencies. The Behavioural Inhibition System scale consists of 7 items with a score range of 7-28, with higher scores indicating higher behavioural inhibition. The Behavioural Activation System scale comprises three subscales: Drive (4 items; score range 4-16), Fun Seeking (4 items; score range 4-16), and Reward Responsiveness (5 items; score range 5-20). Higher scores on each BAS subscale indicate higher levels of behavioural activation within the corresponding domain.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  5. Emotion regulation function

    The Cognitive Emotion Regulation Questionnaire measures change in emotion regulation functions. The scale comprises nine subscales, Self-Blame, Acceptance, Rumination, Positive Refocusing, Refocus on Planning, Positive Reappraisal, Putting into Perspective, Catastrophising, and Other-Blame. Each consisting of 2 items with a score range of 2-10. Higher scores on each subscale indicate greater habitual use of emotion regulation strategy.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  6. Coping to adversity

    The Brief Coping Orientation to Problems Experienced inventory measures change in people's coping strategies to hardships. The problem-focused subscale consist of 8 items (score range 4-32). The emotion-focused subscale consists of 12 items (score range 4-46). The avoidant/dysfunctional coping subscale consists of 8 items (score range 4-32). In each subscale, higher scores indicate greater use of the corresponding coping strategy.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  7. Reward sensitivity

    The Temporal Experience of Pleasure Scale assesses change in sensitivity towards both anticipatory and consummatory pleasurable experience. The scale comprises four subscales: Abstract Anticipatory Pleasure (4 items; score range 4-24), Contextual Anticipatory Pleasure (5 items; score range 5-30), Abstract Consummatory Pleasure (6 items; score range 6-36), and Contextual Consummatory Pleasure (4 items; score range 4-24), with higher scores on each subscale indicating greater capacity to experience pleasure from reward.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  8. Apathy symptom

    The Apathy Evaluation Scale-Self measures change in emotional indifference and apathy (lack of motivation). The scale consists of 18 items, yielding a total score range of 0-54, with higher scores indicating greater emotional indifference and higher levels of apathy.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  9. Perceived loneliness

    The brief UCLA Loneliness Scale measures change in the participants' subjective loneliness. The scale consists of 6 items yielding a total score range of 6-24, with higher scores indicating higher levels of perceived loneliness.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  10. Stress level

    The 10-item Perceived Stress Scale measures change in perceived stressful experiences. The scale consists of 10 items yielding a total score range of 0-40, with higher scores indicating higher levels of perceived stress.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  11. Emotion ratings of words

    The Emotion Rating Task measures changes in participants' feeling and motivation to positive social, positive non-social, negative social and negative non-social word stimuli.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  12. Instrumental behavioural motivation

    The Monetary Incentive Delay task measures change in behavioural motivations to obtain rewards or to avoid punishment.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  13. Emotional inhibition control

    The Emotion Stroop task measures change in participants' inhibition control of emotional processing.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  14. Cognitive control function

    The colour stroop measures change in cognitive control and inhibition functions.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

  15. Working memory

    The N-back task measures change in the participants' working memory capacity.

    Time frame: Baseline (Day 1), Post-Intervention (Day 15), 1-Month Follow-up (Day 45), 3-Month Follow-up (Day 105)

07

Study locations

1 of 1 sites recruiting
  • The University of Hong Kong
    Hong Kong, Hong Kong
    • Associate Professor, Principle Investigator · Contact · rshao@hku.hk · +852-3917-8927
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07319143
Lead sponsor
The University of Hong Kong
Collaborators
Research Grants Council, Hong Kong
Responsible party
Zhengxi Shao (Associate Professor, The University of Hong Kong) — Principal investigator
First posted
Jan 6, 2026
Start date
Jan 8, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
May 4, 2026

Study contacts

Associate Professor, Principle Investigator
Contact
rshao@hku.hk
+852-3917-8927

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion